Prognostic analysis of childhood T-lymphoblastic lymphoma treated with leukemia regimen

HOU Shu-Min; SHAO Jing-Bo; LI Hong; ZHANG Na; ZHU Jia-Shi; WANG Dan; FU Pan

doi:10.7499/j.issn.1008-8830.2311060

PDF(614 KB)

Chinese Journal of Contemporary Pediatrics ›› 2024, Vol. 26 ›› Issue (5) : 469-475. DOI: 10.7499/j.issn.1008-8830.2311060

CLINICAL RESEARCH

Prognostic analysis of childhood T-lymphoblastic lymphoma treated with leukemia regimen

HOU Shu-Min, SHAO Jing-Bo, LI Hong, ZHANG Na, ZHU Jia-Shi, WANG Dan, FU Pan

Author information +

History +

Abstract

Objective To investigate the prognosis of childhood T-lymphoblastic lymphoma (T-LBL) treated with acute lymphoblastic leukemia (ALL) regimen and related influencing factors. Methods A retrospective analysis was performed for the prognostic characteristics of 29 children with T-LBL who were treated with ALL regimen (ALL-2009 or CCCG-ALL-2015 regimen) from May 2010 to May 2022. Results The 29 children with T-LBL had a 5-year overall survival (OS) rate of 84%±7% and an event-free survival (EFS) rate of 81%±8%. The children with B systemic symptoms (unexplained fever >38°C for more than 3 days; night sweats; weight loss >10% within 6 months) at initial diagnosis had a lower 5-year EFS rate compared to the children without B symptoms (P<0.05). The children with platelet count >400×10⁹/L and involvement of both mediastinum and lymph nodes at initial diagnosis had lower 5-year OS rates (P<0.05). There were no significant differences in 5-year OS and EFS rates between the children treated with CCCG-ALL-2015 regimen and those treated with ALL-2009 regimen (P>0.05). Compared with the ALL-2009 regimen, the CCCG-ALL-2015 regimen reduced the frequency of high-dose methotrexate chemotherapy and the incidence rate of severe infections (P<0.05). Conclusions The ALL regimen is safe and effective in children with T-LBL. Children with B systemic symptoms, platelet count >400×10⁹/L, and involvement of both mediastinum and lymph nodes at initial diagnosis tend to have a poor prognosis. Reduction in the frequency of high-dose methotrexate chemotherapy can reduce the incidence rate of severe infections, but it does not affect prognosis.

Key words

T-lymphoblastic lymphoma / Treatment / Prognosis / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

HOU Shu-Min, SHAO Jing-Bo, LI Hong, ZHANG Na, ZHU Jia-Shi, WANG Dan, FU Pan. Prognostic analysis of childhood T-lymphoblastic lymphoma treated with leukemia regimen[J]. Chinese Journal of Contemporary Pediatrics. 2024, 26(5): 469-475 https://doi.org/10.7499/j.issn.1008-8830.2311060

References

1 Burkhardt B, Hermiston ML. Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities[J]. Br J Haematol, 2019, 185(6): 1158-1170. PMID: 30809797. DOI: 10.1111/bjh.15793.
2 Portell CA, Sweetenham JW. Adult lymphoblastic lymphoma[J]. Cancer J, 2012, 18(5): 432-438. PMID: 23006948. DOI: 10.1097/PPO.0b013e31826b1232.
3 Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report[J]. Blood, 2000, 95(2): 416-421. PMID: 10627444.
4 Si Lim SJ, Ford JB, Hermiston ML. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults[J]. Blood, 2023, 141(25): 3019-3030. PMID: 37018730. DOI: 10.1182/blood.2022016503.
5 Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting[J]. J Clin Oncol, 1989, 7(11): 1630-1636. PMID: 2809679. DOI: 10.1200/JCO.1989.7.11.1630.
6 中国抗癌协会淋巴瘤专业委员会, 中国医师协会肿瘤医师分会, 中国医疗保健国际交流促进会肿瘤内科分会. 中国淋巴瘤治疗指南（2021年版）[J]. 中华肿瘤杂志, 2021, 43(7): 707-735. DOI:10.3760/cma.j.cn112152-20210516-00382.
7 王建祥. 血液病诊疗规范[M]. 北京: 中国协和医科大学出版社, 2014: 127-128.
8 中国抗癌协会小儿肿瘤专业委员会急性淋巴细胞白血病2015多中心研究协作组. CCCG-ALL-2015方案多中心临床报告[J]. 中华儿科杂志, 2022, 60(10): 1002-1010. PMID: 36207846. DOI: 10.3760/cma.j.cn112140-20220719-00895.
9 张之南, 沈悌. 血液病诊断及疗效标准[M]. 3版. 北京: 科学出版社, 2007: 116-121.
10 U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE): version 5.0[Z]. (2017-11-27)[2023-03-01]. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
11 Luca DC. Update on lymphoblastic leukemia/lymphoma[J]. Clin Lab Med, 2021, 41(3): 405-416. PMID: 34304772. DOI: 10.1016/j.cll.2021.04.003.
12 Kroeze E, Loeffen JLC, Poort VM, et al. T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor?[J]. Blood Adv, 2020, 4(14): 3466-3473. PMID: 32722786. PMCID: PMC7391147. DOI: 10.1182/bloodadvances.2020001822.
13 张忠鲁. 恶性肿瘤与发热: 陈年的命题、临床的难题[J]. 中国实用内科杂志, 2000, 20(11): 645-646. DOI: 10.3969/j.issn.1005-2194.2000.11.003.
14 Braun A, Anders HJ, Gudermann T, et al. Platelet-cancer interplay: molecular mechanisms and new therapeutic avenues[J]. Front Oncol, 2021, 11: 665534. PMID: 34322381. PMCID: PMC8311658. DOI: 10.3389/fonc.2021.665534.
15 Dymicka-Piekarska V, Koper-Lenkiewicz OM, Zińczuk J, et al. Inflammatory cell-associated tumors. Not only macrophages (TAMs), fibroblasts (TAFs) and neutrophils (TANs) can infiltrate the tumor microenvironment. The unique role of tumor associated platelets (TAPs)[J]. Cancer Immunol Immunother, 2021, 70(6): 1497-1510. PMID: 33146401. PMCID: PMC8139882. DOI: 10.1007/s00262-020-02758-7.
16 Krishnan A, Thomas S. Toward platelet transcriptomics in cancer diagnosis, prognosis and therapy[J]. Br J Cancer, 2022, 126(3): 316-322. PMID: 34811507. PMCID: PMC8810955. DOI: 10.1038/s41416-021-01627-z.
17 Liu H, Pan W, Tang C, et al. The methods and advances of adaptive immune receptors repertoire sequencing[J]. Theranostics, 2021, 11(18): 8945-8963. PMID: 34522220. PMCID: PMC8419057. DOI: 10.7150/thno.61390.
18 Aran A, Garrigós L, Curigliano G, et al. Evaluation of the TCR repertoire as a predictive and prognostic biomarker in cancer: diversity or clonality?[J]. Cancers (Basel), 2022, 14(7): 1771. PMID: 35406543. PMCID: PMC8996954. DOI: 10.3390/cancers14071771.
19 Burkhardt B, Reiter A, Landmann E, et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin-Frankfurt-Muenster group[J]. J Clin Oncol, 2009, 27(20): 3363-3369. PMID: 19433688. DOI: 10.1200/JCO.2008.19.3367.
20 Hoelzer D, G?kbuget N. Treatment of lymphoblastic lymphoma in adults[J]. Best Pract Res Clin Haematol, 2002, 15(4): 713-728. PMID: 12617872. DOI: 10.1053/beha.2002.0230.
21 李红, 邵静波, 朱嘉莳, 等. 儿童急性淋巴细胞白血病早期治疗反应对预后的预测价值[J]. 临床儿科杂志, 2021, 39(8): 600-604. DOI: 10.3969/j.issn.1000-3606.2021.08.010.
22 Winter SS, Devidas M, Chen S, et al. Capizzi-style methotrexate with pegasparagase (C-MTX) is superior to high-dose methotrexate (HDMTX) in T-lineage acute lymphoblastic leukemia (T-ALL): results from Children's Oncology Group (COG) AALL0434[J]. Blood, 2015, 126(23): 794. DOI: 10.1182/blood.V126.23.794.794.
23 Jastaniah W, Elimam N, Abdalla K, et al. High-dose methotrexate vs. Capizzi methotrexate for the treatment of childhood T-cell acute lymphoblastic leukemia[J]. Leuk Res Rep, 2018, 10: 44-51. PMID: 30416957. PMCID: PMC6215054. DOI: 10.1016/j.lrr.2018.10.001.